Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
wet AMD
Biotech
Outlook's eye disease drug fails to match Lucentis, sinking stock
The biotech brushed off the failure, noting positive details and vowing to seek FDA approval, but investors were less sanguine about the setback.
Nick Paul Taylor
Nov 27, 2024 8:40am
Adverum's gene therapy reduces treatment burden in wet AMD
Feb 8, 2024 11:17am
4DMT links gene therapy to drop in Eylea injections
Feb 5, 2024 6:23am
Eyconis launches with $150M and Ascendis' eye disease meds
Jan 29, 2024 11:03am
Regenxbio-AbbVie in-office gene therapy clears phase 2 test
Jan 17, 2024 9:42am
Kodiak resurrects eye drug after ph. 3 data renew approval plans
Nov 6, 2023 8:40am
